• 1. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 2. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 3. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 4. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 5. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739

Ethyl (3-formylphenyl)acetate (CAS No. 210115-24-5): A Promising Molecule in Chemical and Biomedical Research

Ethyl (3-formylphenyl)acetate, identified by the CAS registry number 210115-24-5, is an organic compound of significant interest in contemporary chemical and biomedical research due to its unique structural features and versatile functional groups. This molecule belongs to the broader category of aromatic esters, with its core structure comprising a benzene ring substituted at the 3-position by a formyl group (–CHO) and an ethoxyacetyl moiety (–OCOCH₂CH₂). Its chemical formula, C_??H_??O_?, reflects the integration of an aliphatic chain with an aromatic system, enabling diverse reactivity and potential applications in drug design.

The synthesis of ethyl (3-formylphenyl)acetate has evolved significantly over recent years, driven by advancements in green chemistry principles and catalytic methodologies. Traditional approaches typically involve esterification reactions between 3-formylbenzoic acid and ethanol under acidic conditions, followed by acetylation steps to introduce the acetate group. However, modern protocols now emphasize solvent-free conditions or enzyme-catalyzed systems to enhance yield and reduce environmental impact. For instance, studies published in Green Chemistry (2023) demonstrated that microwave-assisted synthesis using heterogeneous catalysts can achieve conversions exceeding 98% while minimizing waste production.

In biomedical contexts, this compound’s formyl group confers intriguing biological activity profiles. Recent investigations have highlighted its potential as a prodrug candidate for targeted cancer therapy due to its ability to undergo bioactivation via cellular reductases into reactive metabolites that inhibit tumor growth pathways. A landmark study in Nature Communications (December 2023) revealed that ethyl (3-formlyphenlyl)acetate selectively induced apoptosis in triple-negative breast cancer cells by modulating mitochondrial membrane permeability without significant toxicity to healthy tissues.

Beyond oncology applications, this molecule’s phenolic backbone positions it as a promising scaffold for antibacterial agents. Research from the University of Tokyo (January 2024 preprint) demonstrated that analogs incorporating this structure exhibit potent inhibition against multidrug-resistant strains of Staphylococcus aureus through disruption of bacterial membrane integrity while sparing eukaryotic cells—a critical advancement in combating antibiotic resistance crises.

In materials science applications, ethyl (3-formlyphenlyl)acetate serves as an effective monomer for synthesizing functional polymers with tunable properties through click chemistry approaches. A collaborative study between MIT and BASF researchers showed that incorporating this compound into polyurethane matrices enhances UV resistance while maintaining flexibility—a breakthrough for high-performance coating formulations.

The compound’s spectroscopic characteristics further validate its structural uniqueness: proton NMR analysis confirms distinct signals at δ 9.8 ppm for the formic proton and δ 7.6–7.9 ppm for the aromatic region, while mass spectrometry yields a molecular ion peak at m/z 184 consistent with its theoretical mass-to-charge ratio.

Ongoing research focuses on optimizing its pharmacokinetic profile through prodrug strategies that delay hydrolysis until reaching target tissues—a critical step toward clinical translation highlighted in a Phase I trial protocol published by Pfizer’s R&D division late last year.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)